Trial Profile

An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Biomarkers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary)
Indications Heart failure
Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
Acronyms EMBARK-HFpEF
Sponsors Bristol-Myers Squibb; MyoKardia

05 Sep 2024 According to a The Heart Failure Society of America (HFSA) media release, data from this trial to be presented at Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), Sept 27-30, at the Georgia World Congress Center and the new Signia by Hilton Atlanta in Atlanta, GA.
23 May 2024 Status changed from active, no longer recruiting to completed.
07 Nov 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com